<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905148</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-283/PD-0325901-AU-001</org_study_id>
    <nct_id>NCT03905148</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Participants With Advanced or Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SpringWorks Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 combination in
      Participants with tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A will consist of dose escalation and dose-finding components to establish the max tolerated dose and/or recommended Phase 2 dose Part B will investigate efficacy and further evaluate the PK, safety, and tolerability of the combination of PD-0325901 and BGB-283 (lifirafenib).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>Approximately 2 years from date of the participants enrollment</time_frame>
    <description>Incidence and severity of AEs and SAEs and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of DLT events and treatment-emergent AEs (TEAEs)</measure>
    <time_frame>Approximately 2 years from date of the participants enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in subjects with selected tumor types</measure>
    <time_frame>Approximately 2 years from date of the participants enrollment</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Part A: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-0325901 at 2 mg once a day and BGB-283 (lifirafenib) at 15 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-0325901 at 2 mg once a day and BGB-283 (lifirafenib) at 20 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-0325901 at 4 mg once a day and BGB-283 (lifirafenib) at 20 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-0325901 at 6 or 8 mg once a day and BGB-283 (lifirafenib) at 20 or 25 mg once a day depending on the safety and tolerability observed at Levels 1, 2, and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-small cell lung cancer with confirmed K-RAS mutations, approximately 15 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial cancer with confirmed K-RAS mutations, approximately 15 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor type of interest based on preliminary anti-tumor clinical activities observed in Part A, approximately 15 participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-283 (lifirafenib)</intervention_name>
    <description>RAF Dimer Inhibitor</description>
    <arm_group_label>Part A: Dose Level 1</arm_group_label>
    <arm_group_label>Part A: Dose Level 2</arm_group_label>
    <arm_group_label>Part A: Dose Level 3</arm_group_label>
    <arm_group_label>Part A: Dose Level 4</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0325901</intervention_name>
    <description>MEK Inhibitor</description>
    <arm_group_label>Part A: Dose Level 1</arm_group_label>
    <arm_group_label>Part A: Dose Level 2</arm_group_label>
    <arm_group_label>Part A: Dose Level 3</arm_group_label>
    <arm_group_label>Part A: Dose Level 4</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Able to provide informed consent

          2. Age 18 on day of signing informed consent form (ICF) or of the legal age of consent in
             the jurisdiction in which the study is taking place

          3. Advanced or metastatic, unresectable tumors who have experienced disease progression

               -  Part A: NSCLC, CRC, ovarian cancer, endometrial cancer, thyroid cancer, melanoma,
                  pancreatic cancer, and other)

               -  Part B: Group 1: NSCLC, Group 2: endometrial cancer, Group 3: Tumor types of
                  interest based on preliminary anti-tumor activities observed in Part A

          4. Must have archival tumor tissue or agree to tumor biopsy

          5. Measureable disease per RECIST 1.1

          6. Eastern Cooperative Oncology Group performance status of greater than 1

          7. Life expectancy is greater than 12 weeks at the of signing ICF.

          8. Adequate organ function and no transfusion within 14 days of first dose.

          9. Females are of non-child bearing potential or willing to use contraception.

         10. Males vasectomized or agree to use contraception.

        Key Exclusion Criteria:

          1. Central Nervous System metastasis

          2. Any retinal pathology considered to be a risk factor for central serous retinopathy

          3. History of glaucoma

          4. Active parathyroid disorder or history of malignancy associated hypercalcemia

          5. Clinically significant cardiac disease within the past 6 months of signing ICF.

          6. LVEF less than 50%

          7. Abnormal QT interval at Screening

          8. Severe uncontrolled systemic disease

          9. HIV

         10. Clinically significant active or known history of liver disease. (Hepatitis B and
             Hepatitis C)

         11. Hemorrhage or bleeding event at NCI-CTCAE v4.03 Grade 3 or higher within 28 days of
             first dose.

         12. Increased serum calcium

         13. Inability to swallow oral medications

         14. Ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks. No
             immunotherapy,biologic therapy, hormonal, or molecular targeted therapy within prior 2
             weeks

         15. Concomitant systemic or glucocorticoid therapy

         16. Concomitant vitamin D

         17. Major surgical procedure or significant traumatic injury within 4 weeks prior to first
             dose or anticipates need for major surgery while on study

         18. Concomitant medicines that are strong CYP3A inhibitors

         19. History of significant toxicity from another RAF, MEK, ERK inhibitor requiring
             discontinuation of treatment from these drugs

         20. Underlying medical conditions in investigator's opinion to be unfavorable to be a part
             of the study

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Singh, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1 (877) 828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blacktown Cancer and Haematology Centre</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Prince of Wales Private Hospital - Specialist Medical Randwick</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. J Clin Oncol. 2020 Jul 1;38(19):2140-2150. doi: 10.1200/JCO.19.02654. Epub 2020 Mar 17.</citation>
    <PMID>32182156</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

